Clinical trials: Acute Leukemias
B-cell Acute Lymphoblastic Leukemia
A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL)
This is a multi-center, phase I/II trial to evaluate the safety and efficacy of HY004 treatment in Adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-cell ALL).
- Trial name
- B-ALL (NCT06009107)
- Testing
- HY004, Cyclophosphamide, Fludarabine Phosphate
- Sponsor
- Juventas Cell Therapy Ltd.
Melanoma Stage III, B-cell Non Hodgkin Lymphoma
Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
The goal of this Long-Term Follow-Up Trial is to assess long-term safety and efficacy of Miltenyi CAR T treatment.
- Conditions
- Melanoma Stage III, B-cell Non Hodgkin Lymphoma, Pediatric ALL, Childhood Non-Hodgkin Lymphoma
- Trial name
- LONGSAFE (NCT06508775)
- Testing
- MB-CART19.1, MB-CART20.1, MB-CART2019.1
- Where
- 7 sites in Germany
- Volunteers
- 40 people
- Sponsor
- Miltenyi Biomedicine GmbH
Acute Leukaemia
A Safety and Efficacy Study of Eltrombopag in Subjects With AML
The purpose of this randomized, blinded, placebo-controlled study was to provide clinical safety and exploratory efficacy data on the use of Eltrombopag in adult subjects with Acute Myeloid Leukemia (AML) receiving standard…
- Trial name
- NCT01890746
- Testing
- Daunorubicin, Cytarabine, Eltrombopag
- Where
- 42 sites in United States, Australia and 8 more
- Volunteers
- 148 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia, Lymphocytic, Acute, Leukemia, Nonlymphocytic, Acute
Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies
This study primarily determined the safety and tolerability of escalating doses of vosaroxin (SNS-595) in 2 dose schedules, and assessed the PK profile of vosaroxin and defined a recommended dose regimen for Phase 2 studies.
- Conditions
- Leukemia, Lymphocytic, Acute, Leukemia, Nonlymphocytic, Acute, Leukemia, Myeloid, Chronic, Myelodysplastic Syndromes
- Trial name
- NCT00246662
- Testing
- Vosaroxin
- Where
- 5 sites in United States
- Volunteers
- 75 people
- Sponsor
- Sunesis Pharmaceuticals
Acute Myeloid Leukemia
Study of GDX012 in Patients With MRD Positive AML
The purpose of this first-in-human study is to assess the safety, tolerability, antileukemic activity and maximum tolerated dose (MTD) of GDX012 in AML patients who are MRD positive by multiparametric flow cytometry.
- Trial name
- NCT05001451
- Testing
- GDX012 Suspension for IV Infusion
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- GammaDelta Therapeutics Limited
Acute Myeloid Leukemia (AML) With, FLT3 Mutation, Internal Tandem Duplication (ITD) or Tyrosine Kinase Domain (TKD)
Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy
The purpose of this study is to provide access to Midostaurin and gather additional safety data on the combination of Midostaurin and standard of care for adult patients with newly diagnosed Fms-like tyrosine kinase receptor…
- Trial name
- AMLFLT3 (NCT02624570)
- Testing
- Midostaurin
- Where
- 44 sites in United States
- Sponsor
- Novartis Pharmaceuticals
Acute Myeloid Leukemia, Myelodysplastic Syndromes
A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome
RO6870810 (formerly TEN-010) is a small molecule, bromodomain and extra-terminal (BET) bromodomain inhibitor. This study is designed to characterize the safety, tolerability, and pharmacokinetics of RO6870810 monotherapy in…
- Trial name
- NCT02308761
- Testing
- RO6870810
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Hoffmann-La Roche
Acute Myeloid Leukemia, Myelodysplastic Syndromes
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft"/"Orca-Q") in participants undergoing allogeneic hematopoietic cell transplant (alloHCT) transplantation for hematologic…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia, Acute Lymphoblastic Leukemia
- Trial name
- NCT03802695
- Testing
- OrcaGraft (Orca-Q)
- Where
- 12 sites in United States
- Volunteers
- 300 people
- Sponsor
- Orca Biosystems, Inc.
Acute Myeloid Leukemia (AML)
Characteristics and Outcomes of Acute Myeloid Leukemia (AML) Patients Treated With Oral-Azacitidine Maintenance Therapy in France
The purpose of this study is to collect and evaluate real-world data to describe the outcomes, patient characteristics, safety profile and treatment patterns of oral azacitidine prescribed as maintenance treatment after frontline…
- Trial name
- RELION (NCT06565975)
- Testing
- Oral azacitidine
- Where
- France
- Volunteers
- 112 people
- Sponsor
- Bristol-Myers Squibb
Acute Lymphocytic Leukemia
A Study to Learn About the Safety of BESPONSA Injection in Pediatric Patients With Acute Lymphocytic Leukemia.
The purpose of this study is to learn about the safety of BESPONSA for pediatric patients. . BESPONSA is approved for treatment of relapsed or refractory CD22-positive acute lymphocytic leukemia for pediatric patients.
- Trial name
- NCT06476665
- Where
- Japan
- Volunteers
- 12 people
- Sponsor
- Pfizer
Acute Myeloid Leukemia (AML), FLT3-mutated Acute Myeloid Leukemia
A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia
People with acute myeloid leukemia (AML) are usually treated with chemotherapy. Some people with AML have a changed FLT3 gene which causes leukemia cells to grow faster.
- Trial name
- NCT05520567
- Testing
- Gilteritinib, Venetoclax, Azacitidine
- Where
- 18 sites in United States
- Volunteers
- 70 people
- Sponsor
- Astellas Pharma Global Development, Inc.
MDS, AML
Non-interventional Study With Azacitidin (Vidaza®)
The purpose of this non-interventional study is to collect data on the efficiency and safety of Azacitidin in the routine application.
- Conditions
- MDS, AML, CMMOL
- Trial name
- Piaza (NCT01192945)
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- iOMEDICO AG
Acute Myeloid Leukemia
A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia
The purpose of this study is to examine the safety and efficacy of decitabine in sequential administration with cytarabine in children with relapsed or refractory acute myeloid leukemia (AML).
- Trial name
- NCT01853228
- Testing
- Phase1 and Phase 2: decitabine, Phase 1: cytarabine, Phase 2: cytarabine
- Where
- 17 sites in Belgium, Denmark and 5 more
- Volunteers
- 17 people
- Sponsor
- Janssen Research & Development, LLC
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha
During the Core Phase of the study, participants received STI571 at a dose of 400 milligrams (mg) daily for up to 12 months. Participants completing 12 months of therapy were eligible to continue treatment in the Extension Phase…
- Trial name
- NCT00171223
- Testing
- STI571
- Where
- 28 sites in United States, France and 4 more
- Volunteers
- 532 people
- Sponsor
- Novartis Pharmaceuticals
Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment
To assess the impact of moderate hepatic impairment on cytarabine and daunorubicin pharmacokinetics and their metabolites following administration of CPX-351.
- Conditions
- Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS)
- Trial name
- NCT02269579
- Testing
- CPX-351
- Where
- 5 sites in United States
- Sponsor
- Jazz Pharmaceuticals
Breast Cancer, Lung Cancer
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
The goal of this study is to create a data set to add to Carevive's registry from real world clinical and patient reported data collected using an electronic care planning system (CPS) with remote symptom monitoring that is used…
- Conditions
- Breast Cancer, Lung Cancer, Multiple Myeloma, Ovarian Cancer
- Trial name
- NCT05974150
- Testing
- Web based survey
- Where
- 7 sites in United States
- Volunteers
- 25 people
- Sponsor
- Carevive Systems, Inc.
Acute Lymphocytic Leukemia
Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia
The Phase 1 portion of this study will assess the safety, tolerability and efficacy at increasing dose levels of inotuzumab ozogamicin in subjects with CD22-positive relapsed or refractory adult acute lymphocytic leukemia (ALL)…
- Trial name
- NCT01363297
- Testing
- Inotuzumab Ozogamicin
- Where
- 15 sites in United States
- Volunteers
- 72 people
- Sponsor
- Pfizer
Myelodysplastic Syndromes, Higher Risk Myelodysplastic Syndromes
Study of REM-422 in Patients With AML or Higher Risk MDS
The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with Higher Risk MDS and relapsed/refractory AML
- Conditions
- Myelodysplastic Syndromes, Higher Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, Acute Myeloid Leukemia Refractory
- Trial name
- NCT06297941
- Testing
- REM-422
- Where
- 9 sites in United States, France
- Volunteers
- 100 people
- Sponsor
- Remix Therapeutics
Solid Tumors, Acute Myeloid Leukemia
A Study of PLX51107 in Advanced Malignancies
The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the investigational drug PLX51107 in subjects with advanced solid tumors (including lymphoma), and advanced…
- Conditions
- Solid Tumors, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma
- Trial name
- NCT02683395
- Testing
- PLX51107
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Plexxikon
Acute Myeloid Leukemia (AML)
Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)
A Phase 1/2 dose escalation study of BCL-2 Inhibitor ZN-d5 and the Wee1 Inhibitor ZN-c3 in Subjects with Acute Myeloid Leukemia (AML).
- Trial name
- NCT05682170
- Testing
- ZN-d5 ZN-c3, ZN-c3
- Where
- 13 sites in United States
- Volunteers
- 40 people
- Sponsor
- K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.